Sunshine Biopharma Introduces Everolimus in Canada, Tapping into a $2.5 Billion Global Oncology Market

DENVER, Colo., Apr 21, 2025 (247marketnews.com) – Sunshine Biopharma (NASDAQ:SBFM) stated that its wholly owned Canadian subsidiary, Nora Pharma, launched Everolimus in Canada’s generic prescription drug market. Everolimus, a generic equivalent of Afinitor, is approved for treating advanced renal cell carcinoma, HER2-negative breast cancer in post-menopausal women, progressive neuroendocrine tumors of pancreatic, gastrointestinal, or lung origin, and subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Nora Pharma’s Everolimus is available in 2.5 mg, 5 mg, and 10 mg strengths, packaged in 30-tablet blister packs.

Dr. Steve Slilaty, Sunshine Biopharma’s CEO, commented, “Our presence in the industry is propelled by a relentless pursuit of progress. Through continued investment in cutting-edge technologies, breakthrough research, and strategic partnerships, we are advancing solutions that create lasting impact for patients.”

According to DATAINTELO, the global Everolimus market was valued at $2.5 billion in 2023 and is projected to grow at a 7.1% CAGR, reaching approximately $4.8 billion by 2032. The Canadian market, accounting for roughly 2.2% of the global share, is expected to grow at a 6.4% CAGR, per IQVIA Pharmafocus 2027.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (SBFM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.